Clinical Research Directory
Browse clinical research sites, groups, and studies.
Topical Sirolimus in Chemoprevention of Facial Squamous Cell Carcinomas in Solid Organ Transplant Recipients (SiroSkin)
Sponsor: Melanoma and Skin Cancer Trials Limited
Summary
01.21 SiroSkin is a phase 3, double-blind, multi-centre, parallel-arm, randomised, placebo-controlled trial to evaluate the use of topical 1% sirolimus in the chemoprevention of skin cancer, versus placebo, applied every night for 24 weeks in solid organ transplant recipients.
Official title: A Randomised Double-blind Placebo-controlled Trial of Topical Sirolimus in Chemoprevention of Facial Squamous Cell Carcinomas in Solid Organ Transplant Recipients
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
146
Start Date
2024-02-09
Completion Date
2027-09-30
Last Updated
2025-09-09
Healthy Volunteers
No
Interventions
Sirolimus Topical Cream
The intervention topical cream consists of sirolimus 1% in a vehicle. Patients randomised to the intervention will be required to apply the sirolimus topical cream to their face for 6 months
Placebo
Cream containing only the base, or vehicle.
Locations (6)
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia
Westmead Hospital
Westmead, New South Wales, Australia
The Prince Charles Hospital
Chermside, Queensland, Australia
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia
Skin Health Institute
Carlton, Victoria, Australia
The Alfred Hospital
Melbourne, Victoria, Australia